Phase IV Study Evaluating Vunakizumab for Moderate-to-Severe Plaque Psoriasis in Adults Without Prior Biologic Treatment

What this Trial Is About

Researchers are evaluating vunakizumab, a humanized IL-17A inhibitor, in adults with moderate-to-severe chronic plaque psoriasis. This large, multicenter, prospective observational study aims to understand the drugs effectiveness and safety in a Chinese population. The study also explores how vunakizumab affects special psoriasis sites, comorbidities, quality of life, and mental health through patient-reported outcomes and satisfaction surveys. Participants receive vunakizumab through subcutaneous injections at a recommended dose of 240 mg, given at weeks 0, 2, 4, and then every 4 weeks up to week 48, with the exact regimen based on the clinicians advice. The study includes a 7-day screening period, a 52-week treatment period, and an 8-week safety follow-up period. During the study, patients undergo clinical assessments to measure skin lesion clearance rates and improvements in psoriasis severity using PASI scores at various time points up to 52 weeks. Researchers also monitor treatment satisfaction and responses according to ACR criteria at several intervals. Safety is tracked during the follow-up period, with the total participation lasting over a year.

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis